Viridian Therapeutics, Inc.
General ticker "VRDN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.3B (TTM average)
Viridian Therapeutics, Inc. follows the US Stock Market performance with the rate: 52.9%.
Estimated limits based on current volatility of 2.4%: low 31.01$, high 32.55$
Factors to consider:
- Total employees count: 143 (+52.1%) as of 2024
- Top business risk factors: Supply chain disruptions, Commercial launch failure, Third-party risks, Reimbursement and pricing pressures, Manufacturing risks
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.67$, 30.79$]
- 2025-12-31 to 2026-12-31 estimated range: [6.75$, 20.73$]
Financial Metrics affecting the VRDN estimates:
- Negative: with PPE of -5.1 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.74 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.23 <= 0.79
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Positive: Inventory ratio change, % of -0.97 <= -0.75
Short-term VRDN quotes
Long-term VRDN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.77MM | $0.31MM | $0.30MM |
| Operating Expenses | $136.08MM | $254.76MM | $299.34MM |
| Operating Income | $-134.30MM | $-254.45MM | $-299.04MM |
| Non-Operating Income | $4.43MM | $16.72MM | $29.09MM |
| Interest Expense | $0.49MM | $1.85MM | $3.05MM |
| R&D Expense | $100.89MM | $159.76MM | $238.25MM |
| Income(Loss) | $-129.87MM | $-237.73MM | $-269.95MM |
| Profit(Loss)* | $-129.87MM | $-237.73MM | $-269.95MM |
| Stockholders Equity | $395.06MM | $442.02MM | $671.64MM |
| Inventory | $6.62MM | $0.00MM | $0.00MM |
| Assets | $435.09MM | $490.42MM | $742.40MM |
| Operating Cash Flow | $-93.84MM | $-184.17MM | $-232.32MM |
| Capital expenditure | $0.80MM | $0.90MM | $0.51MM |
| Investing Cash Flow | $-115.13MM | $-94.25MM | $-228.65MM |
| Financing Cash Flow | $322.24MM | $225.67MM | $457.74MM |
| Earnings Per Share** | $-4.05 | $-5.31 | $-3.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.